SEC Form 4 · accession 0001209191-18-036656
ImmunoCellular Therapeutics, Ltd. · IMUC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John S Yu
Director
Period of report
Jun 6, 2018
Accepted (ET)
Jun 8, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822411
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 6, 2018 | A | 120,000 | $0.00 | A | 120,250 | D | |
| Common Stock | holding | — | — | — | 258 | I | By Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of ImmunoCellular Therapeutics Ltd. common stock.
- F2The restricted stock unit shall be fully vested and immediately exercisable on the grant date.